International Clinical Trial: FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446465) titled 'FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Ye Xu

Condition: Colorectal Cancer (Locally Advanced or Metastatic) Colorectal Cancer Microsatellite Stable (MSS)

Intervention: Drug: Serplulimab Drug: Fruquintinib

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: March 1, 2026

Target Sample Si...